You are here

Zhansheng Weige Chaoyue Xilishi tablets

Safety advisory

18 July 2014

Zhansheng Weige Chaoyue Xilishi tablets pose a serious risk to your health and should not be taken.

The Therapeutic Goods Administration (TGA) has tested a product labelled Zhansheng Weige Chaoyue Xilishi and found that:

  • Packaging for Zansheng Weige Chaoyue Xilishi tabletsit contains the undeclared prescription substance sildenafil.
  • consumers are advised that sildenafil is a prescription-only medicine

The supply of Zhansheng Weige Chaoyue Xilishi tablets is illegal.

Zhansheng Weige Chaoyue Xilishi tablets have not been assessed by the TGA for quality, safety or efficacy as required under Australian legislation, and the place of manufacture is not approved by the TGA.

TGA investigations have shown that a number of people in Australia have bought the product online.

Information for consumers

  • Stop taking Zhansheng Weige Chaoyue Xilishi tablets and take any remaining tablets to your local pharmacy for safe disposal.
  • If you have any concerns arising from your use of this product, consult your health care practitioner.

Action the TGA is taking

The TGA is working with Australian Customs and Border Protection Service (ACBPS) to help stop future shipments of Zhansheng Weige Chaoyue Xilishi tablets from entering Australia.

If these tablets are found at the border by ACBPS they will be seized and destroyed.

The TGA is advising consumers to exercise extreme caution when purchasing medicines from unknown overseas Internet sites. Products purchased over the Internet:

  • may contain undisclosed and potentially harmful ingredients
  • may not meet the same standards of quality, safety and efficacy as those approved by the TGA for supply in Australia.

Report counterfeit medicines and medical devices

If you are worried about counterfeit medicines or medical devices, and want to report an issue, you can report the matter to the TGA:

Phone: 1800 020 653
Online: Report a perceived breach of the Therapeutic Goods Act or questionable practices relating to therapeutic products